These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9163574)

  • 1. Antagonist activity of [Thr18,gamma-methylleucine19]endothelin-1 in human endothelin receptors.
    Masuda Y; Sugo T; Kikuchi T; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
    Eur J Pharmacol; 1997 May; 325(2-3):263-70. PubMed ID: 9163574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies.
    Wu-Wong JR; Dixon DB; Chiou WJ; Sorensen BK; Liu G; Jae HS; Tasker A; von Geldern TW; Winn M; Opgenorth TJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():107S-111S. PubMed ID: 12193066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors.
    Masuda Y; Sugo T; Kikuchi T; Kawata A; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
    J Pharmacol Exp Ther; 1996 Nov; 279(2):675-85. PubMed ID: 8930171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells.
    Aramori I; Nirei H; Shoubo M; Sogabe K; Nakamura K; Kojo H; Notsu Y; Ono T; Nakanishi S
    Mol Pharmacol; 1993 Feb; 43(2):127-31. PubMed ID: 8429819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Lis EV; Pettibone DJ; Clineschmidt BV; Krause SM; Veber DF; Naylor EM; Chakravarty PK; Walsh TF; Dhanoa DM; Chen A; Bagley SW; Fitch KJ; Greenlee WJ
    Life Sci; 1996; 58(14):1149-57. PubMed ID: 8614266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
    Wu-Wong JR; Dixon DB; Chiou WJ; Dayton BD; Novosad EI; Adler AL; Wessale JL; Calzadilla SV; Hernandez L; Marsh KC; Liu G; Szczepankiewicz B; von Geldern TW; Opgenorth TJ
    Eur J Pharmacol; 1999 Feb; 366(2-3):189-201. PubMed ID: 10082200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of big-endothelin-1 elicits an endothelin ETA receptor-mediated response in endothelial cells.
    N'Diaye N; Pueyo ME; Battle T; Ossart C; Guédin D; Michel JB
    Eur J Pharmacol; 1997 Mar; 321(3):387-96. PubMed ID: 9085052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin-1 analogues substituted at both position 18 and 19: highly potent endothelin antagonists with no selectivity for either receptor subtype ETA or ETB.
    Kikuchi T; Kubo K; Ohtaki T; Suzuki N; Asami T; Shimamoto N; Wakimasu M; Fujino M
    J Med Chem; 1993 Dec; 36(25):4087-93. PubMed ID: 8258832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ET(A) and ET(B) specific ligands synergistically antagonize endothelin-1 binding to an atypical endothelin receptor in primary rat astrocytes.
    Jensen N; Hasselblatt M; Sirén AL; Schilling L; Schmidt M; Ehrenreich H
    J Neurochem; 1998 Feb; 70(2):473-82. PubMed ID: 9453540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors.
    Buchan KW; Alldus C; Christodoulou C; Clark KL; Dykes CW; Sumner MJ; Wallace DM; White DG; Watts IS
    Br J Pharmacol; 1994 Aug; 112(4):1251-7. PubMed ID: 7952888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of TA-0201, an endothelin receptor antagonist, with recombinant and human prostate endothelin receptors.
    Takahashi M; Taniguchi T; Tanaka T; Kanamaru H; Okada K; Muramatsu I
    Eur J Pharmacol; 2003 Apr; 467(1-3):185-9. PubMed ID: 12706473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors.
    Nambi P; Elshourbagy N; Wu HL; Pullen M; Ohlstein EH; Brooks DP; Lago MA; Elliott JD; Gleason JG; Ruffolo RR
    J Pharmacol Exp Ther; 1994 Nov; 271(2):755-61. PubMed ID: 7965793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin binding to NG108-15 cells: evidence for conventional ETA and ETB receptor subtypes and super-high affinity binding components.
    Angelova K; Ergul A; Narayan P; Puett D
    Cell Mol Biol (Noisy-le-grand); 1996 Dec; 42(8):1243-57. PubMed ID: 8997527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation characteristics of endothelin receptor agonists and antagonists in cloned human type-B endothelin receptor.
    Chiou WJ; Magnuson SR; Dixon D; Sundy S; Opgenorth TJ; Wu-Wong JR
    Endothelium; 1997; 5(3):179-89. PubMed ID: 9272381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental diabetes upregulates the expression of uretereral endothelin receptors.
    Nakamura I; Saito M; Fukumoto Y; Yoshida M; Nishi K; Weiss RM; Latifpour J
    Peptides; 1997; 18(7):1091-3. PubMed ID: 9357071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Ca2+ channels and G proteins involved in arachidonic acid release by endothelin-1/endothelinA receptor.
    Kawanabe Y; Nozaki K; Hashimoto N; Masaki T
    Mol Pharmacol; 2003 Sep; 64(3):689-95. PubMed ID: 12920205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a novel bifunctional endothelin receptor antagonist, IRL 3630A, on guinea pig respiratory mechanics.
    Makatani M; Fujitani Y; Takimoto M; Oda K; Sasaki Y; Hori S; Inui T; Sakaki J; Okada T; Hoshiko K; Yamamura T
    Eur J Pharmacol; 2000 Oct; 406(1):139-47. PubMed ID: 11011045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for assessing endothelin ETA-receptor antagonists in preclinical studies.
    Okada M; Siegl PK; Nishikibe M
    Methods Find Exp Clin Pharmacol; 2002; 24(6):361-70. PubMed ID: 12224443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.